share_log

Sera Prognostics | 8-K: SERA PROGNOSTICS REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS

Sera Prognostics | 8-K: SERA PROGNOSTICS REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS

Sera Prognostics | 8-K:SERA 預測報告了 2024 年第二季度財務業績
美股SEC公告 ·  2024/08/08 04:19

Moomoo AI 已提取核心訊息

Sera Prognostics reported Q2 2024 revenue of $24,000, down from $123,000 in Q2 2023. The company achieved a 20% reduction in total operating expenses to $9.3 million, leading to a narrower net loss of $8.3 million compared to $10.5 million year-over-year. Research and development expenses increased 19% to $4.4 million, while selling, general and administrative costs decreased 38% to $4.9 million.The company highlighted recent achievements including the publication of positive AVERT PRETERM TRIAL results and conditional approval from New York State for ambient whole-blood collection. The final PRIME study database lock is anticipated by mid-September, with publication targeted for spring pregnancy conferences.Management is executing various cost-effective programs to educate physicians and patients about their PreTRM® Test, including partnerships with medical professional platforms and multi-channel marketing strategies. The company maintains focus on building evidence portfolio and establishing care guidelines to drive adoption and revenue growth.
Sera Prognostics reported Q2 2024 revenue of $24,000, down from $123,000 in Q2 2023. The company achieved a 20% reduction in total operating expenses to $9.3 million, leading to a narrower net loss of $8.3 million compared to $10.5 million year-over-year. Research and development expenses increased 19% to $4.4 million, while selling, general and administrative costs decreased 38% to $4.9 million.The company highlighted recent achievements including the publication of positive AVERT PRETERM TRIAL results and conditional approval from New York State for ambient whole-blood collection. The final PRIME study database lock is anticipated by mid-September, with publication targeted for spring pregnancy conferences.Management is executing various cost-effective programs to educate physicians and patients about their PreTRM® Test, including partnerships with medical professional platforms and multi-channel marketing strategies. The company maintains focus on building evidence portfolio and establishing care guidelines to drive adoption and revenue growth.
Sera Prognostics報告2024年第二季度營業收入爲24,000美元,較2023年第二季度的123,000美元下降。公司實現了營業費用減少20%,降至930萬,導致淨虧損收窄至830萬,同比相比於1050萬。研究與開發費用增加19%,達到440萬,而銷售、一般及行政費用減少38%,降至490萬。公司強調最近的成就,包括正面結果的AVERt PRETERm試驗報告以及來自紐約州的環境全血採集的有條件批准。最終的PRIME研究數據庫預計將在九月中旬鎖定,出版目標爲春季懷孕會議。管理層正在執行各種成本有效的項目,以教育醫生和患者關於他們的PreTRM®測試,包括與醫療專業平台的合作和多渠道營銷策略。公司繼續專注於建立證據組合和制定護理指南,以推動採用和營業收入增長。
Sera Prognostics報告2024年第二季度營業收入爲24,000美元,較2023年第二季度的123,000美元下降。公司實現了營業費用減少20%,降至930萬,導致淨虧損收窄至830萬,同比相比於1050萬。研究與開發費用增加19%,達到440萬,而銷售、一般及行政費用減少38%,降至490萬。公司強調最近的成就,包括正面結果的AVERt PRETERm試驗報告以及來自紐約州的環境全血採集的有條件批准。最終的PRIME研究數據庫預計將在九月中旬鎖定,出版目標爲春季懷孕會議。管理層正在執行各種成本有效的項目,以教育醫生和患者關於他們的PreTRM®測試,包括與醫療專業平台的合作和多渠道營銷策略。公司繼續專注於建立證據組合和制定護理指南,以推動採用和營業收入增長。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息